Alex Rodriguez has issued a statement in response to the report in the Miami New Times today in which patient records were released suggesting that he used performance enhancing drugs as recently as 2012:
“The news report about a purported relationship between Alex Rodriguez and Anthony Bosch are not true. Alex Rodriguez was not Mr. Bosch’s patient, he was never treated by him and he was never advised by him. The purported documents referenced in the story — at least as they relate to Alex Rodriguez — are not legitimate.”
This is a clear attack on the patient records released as unreliable. Earlier, Major League Baseball released its own statement:
“We are always extremely disappointed to learn of potential links between players and the use of performance-enhancing substances. These developments, however, provide evidence of the comprehensive nature of our anti-drug efforts. Through our Department of Investigations, we have been actively involved in the issues in South Florida. It is also important to note that three of the players allegedly involved have already been disciplined under the Joint Drug Program.
“The recommendations of the Mitchell Report have once again played a critical role in Major League Baseball’s ongoing efforts against performance-enhancing drugs. MLB implemented all of the recommendations made by Senator Mitchell in 2007, several of which emphasized the significance of installing proactive investigative services.
“The establishment of our Department of Investigations has represented a critical advance in these comprehensive efforts. In the years since its formation, DOI’s work has proven pivotal to bringing to light information regarding the use of performance-enhancing substances. Furthermore, DOI has built strong working relationships with federal and local law enforcement authorities. These relationships are crucial because only law enforcement officials have the capacity to reach those outside the game who are involved in the distribution of illegal performance-enhancing drugs.
“Vigilance remains the key toward protecting the integrity of our game. We have the best and most stringent drug testing policy in professional sports, we continue to work with our doctors and trainers to learn what they are seeing day-to-day and we educate our players about the game’s unbending zero-tolerance approach. We remain fully committed to following all leads and seeking the appropriate outcomes for all those who use, purchase and are involved in the distribution of banned substances, which have no place in our game.
“We are in the midst of an active investigation and are gathering and reviewing information. We will refrain from further comment until this process is complete.”
With this, we are left with a he-said, he-said. It will take more investigation by Major League Baseball and the DEA in order to determine what the significance is of the patient records reported on in the Miami New Times is, if any.
The Mets are currently enjoying the spoils of the best young rotation in the game, but the big question is whether this is just a brief window or the start of sustained success. Given the huge prices on the free agent market, it’s going to be next to impossible to keep the band together, but at least one member of the rotation is open to sticking around for the long-term.
While there haven’t been any talks yet, All-Star right-hander Jacob deGrom told Kevin Kernan of the New York Post that he could see himself discussing an extension with the Mets.
“I’m a little bit older, so I might be more willing to do something like that,’’ deGrom told The Post at Mets pre-camp. “You just have to look at what is fair so both sides get a decent deal. It’s something I’d have to look into and make sure I agree with it.’’
It makes sense from deGrom’s perspective. He broke into the majors later than most prospects, so he’ll be 28 this June. Depending on whether he qualifies as a Super Two, he’ll be arbitration-eligible for the first time after either 2016 or 2017. Either way, he’s under team control through 2020, which means that he’s currently on track to hit free agency after his age-32 season. The market might not be kind to him even if he manages to stay healthy, so it could behoove him to get as much guaranteed money as possible right now. The Mets could always decide to play things year-to-year, but perhaps deGrom would be willing to settle for a discount in order to get them to buy out a free agent year or two. It’s a really interesting situation to think about, but odds are the two sides will wait on contract talks until he’s arbitration-eligible for the first time.
DeGrom owns a 2.61 ERA in 52 starts over his first two seasons in the majors. Among starters, only Zack Greinke, Jake Arrieta, and Clayton Kershaw have a lower ERA since the start of 2014.
The Royals and third baseman Mike Moustakas have avoided arbitration by agreeing to a two-year, $14.3 million deal, reports Jon Heyman of MLB Network.
The deal, which was initially discussed last month, buys out Moustakas’ final two years of arbitration. Jeffrey Flanagan of MLB.com reports that it’s believed he’ll make $5.6 million in 2016 and $8.7 million in 2017.
The 27-year-old Moustakas posted an underwhelming .668 OPS over his first four seasons in the majors, but he enjoyed a big postseason in 2014 before breaking out last season by batting .284/.348/.470 with 22 home runs and 82 RBI.
ESPN’s Jerry Crasnick reported this morning that free agent reliever Tommy Hunter required core muscle repair surgery earlier this offseason. Coming off a disappointing 2015, it’s understandable why he’s still on the market, but it sounds like he has at least one significant lead.
Marc Topkin of the Tampa Bay Times hears that the Rays are having “advanced talks” with Hunter as they attempt to add an experienced arm to their bullpen. Nothing is considered close and Hunter is also talking to other clubs. Meanwhile, the Rays have been in touch with veteran reliever Ryan Webb while monitoring the trade market.
Hunter posted a 2.88 ERA as a late-inning arm from 2013-2014, but he compiled a mediocre 4.18 ERA over 58 appearances last season between the Orioles and Cubs. On the bright side, his velocity has held steady and his control is still very good. Despite the down year and core muscle surgery, Topkin writes that Hunter may be holding out for a multi-year deal.
Eric O'Flaherty wasn’t the only reclamation project added by the Pirates today, as the club also announced that they have signed left-hander Cory Luebke to a minor league contract with an invitation to spring training.
Luebke once looked like a solid rotation piece for the Padres, but he hasn’t thrown a pitch in the majors since April 27, 2012. He’s undergone a pair of Tommy John surgeries since. Now 30 years old, he logged seven innings in the minors last season before requiring a procedure to remove loose bodies around a nerve in his forearm. The Padres cut ties with him in November after declining a $7.5 million club option for 2016.
It’s hard to count on much from Luebke at this point, but he told Adam Berry of MLB.com that he feels healthy and hopes to compete for a bullpen job in the spring.